Vaxart Stock Forecast, Price & News

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VXRT shares have increased by 322.7% and is now trading at $8.75.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vaxart.

Vaxart is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Vaxart.

Vaxart Inc (NASDAQ:VXRT) announced its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.06. The biotechnology company earned $0.52 million during the quarter, compared to analyst estimates of $1.90 million. Vaxart had a negative net margin of 281.50% and a negative return on equity of 84.90%.
View Vaxart's earnings history.

Vaxart's stock reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

2 brokerages have issued 1-year price objectives for Vaxart's stock. Their forecasts range from $17.00 to $22.00. On average, they anticipate Vaxart's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 122.9% from the stock's current price.
View analysts' price targets for Vaxart.

Vaxart saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 13,840,000 shares, an increase of 110.3% from the July 30th total of 6,580,000 shares. Based on an average daily trading volume, of 25,980,000 shares, the days-to-cover ratio is presently 0.5 days.
View Vaxart's Short Interest.

Some companies that are related to Vaxart include Ablynx (ABLYF), Denali Therapeutics (DNLI), bluebird bio (BLUE), Halozyme Therapeutics (HALO), Fate Therapeutics (FATE), Immunovant (IMVT), Twist Bioscience (TWST), Legend Biotech (PCVX), Sorrento Therapeutics (SRNE), Kodiak Sciences (KOD), SpringWorks Therapeutics (SWTX), Revolution Medicines (RVMD), Mesoblast (MESO), Editas Medicine (EDIT) and BAVARIAN NORDIC/S (BVNRY).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), Novavax (NVAX), ADMA Biologics (ADMA), OrganiGram (OGI) and Heat Biologics (HTBX).

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Vaxart's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (0.37%), UBS Group AG (0.28%), Prudential Financial Inc. (0.27%), Jane Street Group LLC (0.19%), Hussman Strategic Advisors Inc. (0.18%) and Artal Group S.A. (0.18%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart.

VXRT stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., and Advisor Group Holdings Inc.. Company insiders that have sold Vaxart company stock in the last year include Armistice Capital, Llc, and Todd C Davis.
View insider buying and selling activity for Vaxart.

VXRT stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Prudential Financial Inc., UBS Group AG, Jane Street Group LLC, Artal Group S.A., Nuveen Asset Management LLC, Charles Schwab Investment Management Inc., and Balyasny Asset Management LLC. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart.

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VXRT stock can currently be purchased for approximately $8.75.

Vaxart has a market capitalization of $955.52 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe.

The official website for Vaxart is www.vaxart.com.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]